Tweet Douglas Loe, a health care and biotech analyst with Euro Pacific Canada, discussed the state of the sector today in an interview with BNN’s Pamela Richie. Mr. Loe’s buy recommendations include Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) and Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND). The interview can be accessed here.
Tweet Larry Andrews will be stepping down from his position as president and CEO of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND). To ensure a smooth transition of responsibilities, Mr. Andrews will remain with the company for a period of time while the board undertakes a search process. He will then continue working with Cipher in a consulting […]
Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has reported fourth quarter profit of $17-million or 69 cents a share, compared with $1.5-million or 6 cents in the 2012 quarter. Revenue rose to $12.5-million from $2.9-million. “Strong performance from Absorica, including a sales milestone we achieved in the fourth quarter, helped drive significant revenue and earnings growth in […]
Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has appointed Gerald McDole as chairman, effective immediately, replacing William Garriock, who resigned on Dec. 31, 2013. Mr. McDole has been a member of the Cipher board since 2004. He retired as president and CEO of AstraZeneca Canada’s pharmaceutical operations at the end of 2003.
Tweet Cipher Pharmaceuticals’ (OTCBB:CPHMF; TSX:DND) marketing partner for Absorica has reached a cumulative sales milestone in accordance with the parties’ commercial agreement, triggering a one-time $5-million payment to Cipher. The company said the revenue would be included in its fourth quarter 2013 financial results, which it plans to report in late February. Absorica is an […]
Tweet Third quarter net income for Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) rose to $3.4-million, or 14 cents a share, from $754,000, or 3 cents, in the year earlier quarter. Net revenue climbed to $5.6-million from $2.1-million. “Absorica performed well again in the third quarter, with market share increasing to 17.3% by September from 13.1% in June, […]
Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), in response to questions from shareholders about a Paragraph IV Certification received by its U.S. marketing partner, Ranbaxy Laboratories, has posted on its website some of the most frequently asked questions and Cipher’s response. The Q&A can be accessed here.
Tweet As a result of its annual review, S&P Dow Jones Canadian Index Services is making changes to the S&P/TSX SmallCap Index at the close of trading this Friday, with Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) replacing CML Healthcare Inc.
Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has reported net income of $3.1-million or 13 cents a share on revenue of $5.5-million for the second quarter, compared with $200,000 or 1 cent on revenue of $1.6-million a year earlier. “The continued strong growth of Absorica drove significant gains in our revenue, earnings and cash for the second […]
Tweet At the annual Canadian Dermatology Association Conference in Quebec City over the July 1 weekend, Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) announced the Canadian launch of Epuris, a novel brand formulation of the acne medication isotretinoin for the treatment of severe acne in patients aged 12 years or older. “This represents an important milestone on the path […]